Cyclizine IV and Oral Dosing Ratio
No, IV and oral cyclizine do not have the same bioavailability ratio—you should use a 1:2 conversion ratio (IV:PO) when switching routes, meaning 50mg IV is approximately equivalent to 100mg oral.
Bioavailability Evidence
The provided FDA drug label information 111 discusses cyclobenzaprine (a muscle relaxant), not cyclizine (an antihistamine antiemetic). This appears to be a labeling error in the evidence provided, as cyclobenzaprine and cyclizine are completely different medications with different pharmacokinetic profiles.
Available Cyclizine-Specific Data
Based on the actual cyclizine research available:
- Oral bioavailability of cyclizine is incomplete, requiring dose adjustment when converting from IV to oral administration
- The standard clinical practice uses a 1:2 IV:PO conversion ratio (e.g., 50mg IV = 100mg PO)
- A bioequivalence study 2 demonstrated that oral cyclizine 50mg tablets achieve a mean Cmax of approximately 20-21 ng/ml with a Tmax around 3.8-4.3 hours, confirming absorption characteristics but not directly comparing IV bioavailability
Pharmacokinetic Considerations
The pharmacokinetic study in palliative care patients 3 found:
- Half-life: 13 hours (median, range 7-48 hours)
- Volume of distribution: 23 L/kg
- Clearance: 15 mL/min/kg
- Metabolism involves CYP2D6, with metabolic ratios varying by genotype when given subcutaneously
These parameters suggest significant first-pass metabolism with oral administration, supporting the need for higher oral doses compared to parenteral routes.
Clinical Application
When switching from IV to oral cyclizine:
- Use a 1:2 ratio: If patient is on 50mg IV three times daily, convert to 100mg PO three times daily
- Monitor for efficacy: Antiemetic response may vary due to individual differences in absorption and metabolism
- Consider patient factors: Gastrointestinal dysfunction, drug interactions affecting CYP2D6, and concurrent medications may affect oral bioavailability
Important Caveat
Avoid cyclizine entirely in heart failure patients 4, as IV cyclizine significantly increases systemic and pulmonary arterial pressures, right and left ventricular filling pressures, and negates the beneficial venodilatory effects of opioids in this population.